Chandra Shekar Reddy Ambati (Presenter)
Baylor college of medicine
Bio: I am Chandra shekar reddy Ambati working as research assistant in metabolomics core department of Baylor college of medicine. I had masters in Pharmacology.I have experience in Bio-assays and radio immuno assays.i have been working on biological samples like tissues, Cell lysates, plasma , Cerebrospinal fluid, etc. my works includes sample preparation,and injecting the samples over LC-MS.
Authorship: Chandra shekar reddy ambati
| Short Abstract Ovarian cancer is a serious and one of the top cancer diseases among women which cause more deaths compared to all other types cancers in women. It does not show any symptoms in the early stage and therefore it is very well known as the ‘silent killer’ and not many people will survive from this cancer. The current diagnostic strategies have several limitations and disadvantages. But the good news is that a drug called ‘Olaparib’ has been approved by FDA to treat ovarian cancer patients. This drug stops the activity of a protein called PARP in human body that helps cancer to grow very rapidly. |
Long Abstract
Ovarian cancer is a serious and one of the top cancer diseases among women which cause more deaths compared to all other types cancers in women. It does not show any symptoms in the early stage and therefore it is very well known as the ‘silent killer’ and not many people will survive from this cancer. The current diagnostic strategies have several limitations and disadvantages. But the good news is that a drug called ‘Olaparib’ has been approved by FDA to treat ovarian cancer patients. This drug stops the activity of a protein called PARP in human body that helps cancer to grow very rapidly. Unfortunately, this drug cannot treat all types of cancer patients and it is effective in only a small percentage and also only in advanced stage cancer patients. Because of this reason there is a lot of research going on in the research community to figure out why these kind of drugs are not able to cure all kinds of ovarian cancer patients. Scientists discovered that patients develop resistance to these drugs over the period of time because of their genetics. In this project, by using very advanced technology related to ‘metabolomics’ and ‘biomarkers’, we would like to investigate the drug-resistance changes that are occurring in human biology. This research may lead to discovery of new scientific information which would be helpful to make these drugs work more efficiently, long time and cure the ovarian cancer disease ultimately. This research may also lead to the development of biomarkers to aid in the diagnosis and useful to track the cancer stage.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |